Physician profile
Steven D Chang
NPI 1174598239
$3,537.13
in general payments reported to CMS, 2019-2025
24 companies · $26.92 in 2025
The $26.92 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,487 · 2020: $415 · 2021: $593 · 2022: $276 · 2023: $228 · 2024: $511 · 2025: $26.92.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $766.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $766.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $808.51 | 2019 | |
| Alcon Vision LLC | $499.97 | 2019-2024 | Clareon, Rocklatan |
| Sun Pharmaceutical Industries INC. | $463.06 | 2019-2024 | Cequa |
| Allergan, INC. | $286.36 | 2019-2021 | |
| Dompe US, INC. | $242.48 | 2021-2025 | Oxervate |
| Abbvie INC. | $231.58 | 2022-2024 | Lumigan, Alphagan P, Vuity |
| Aerie Pharmaceuticals, INC. | $174.59 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $120.20 | 2020-2021 | |
| Oyster Point Pharma, INC. | $111.17 | 2022-2024 | Tyrvaya, Ryzumvi |
| Akorn Operating Company LLC | $71.70 | 2021 | |
| Eyevance Pharmaceuticals LLC | $71.43 | 2019-2020 | |
| Bausch & Lomb Americas INC. | $68.06 | 2022-2024 | Miebo |
| Sight Sciences, INC. | $55.38 | 2019-2022 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $48.44 | 2021 | |
| Tarsus Pharmaceuticals, INC. | $47.75 | 2024 | Xdemvy |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Akorn, INC. | $43.87 | 2019-2020 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $32.80 | 2024 | Vevye |
| Ocular Therapeutix, INC. | $24.16 | 2020 | |
| Kala Pharmaceuticals, INC. | $23.76 | 2019 | |
| Thea Pharma INC. | $20.46 | 2024 | Iyuzeh |
| Glaukos Corporation | $19.30 | 2020 | |
| Amgen INC. | $18.33 | 2024 | Tepezza |
| Biotissue Holdings INC. | $14.97 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Chang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.